Skip to Content
Merck

Sox5 regulates beta-cell phenotype and is reduced in type 2 diabetes.

Nature communications (2017-06-07)
A S Axelsson, T Mahdi, H A Nenonen, T Singh, S Hänzelmann, A Wendt, A Bagge, T M Reinbothe, J Millstein, X Yang, B Zhang, E G Gusmao, L Shu, M Szabat, Y Tang, J Wang, S Salö, L Eliasson, I Artner, M Fex, J D Johnson, C B Wollheim, J M J Derry, B Mecham, P Spégel, H Mulder, I G Costa, E Zhang, A H Rosengren
ABSTRACT

Type 2 diabetes (T2D) is characterized by insulin resistance and impaired insulin secretion, but the mechanisms underlying insulin secretion failure are not completely understood. Here, we show that a set of co-expressed genes, which is enriched for genes with islet-selective open chromatin, is associated with T2D. These genes are perturbed in T2D and have a similar expression pattern to that of dedifferentiated islets. We identify Sox5 as a regulator of the module. Sox5 knockdown induces gene expression changes similar to those observed in T2D and diabetic animals and has profound effects on insulin secretion, including reduced depolarization-evoked Ca2+-influx and β-cell exocytosis. SOX5 overexpression reverses the expression perturbations observed in a mouse model of T2D, increases the expression of key β-cell genes and improves glucose-stimulated insulin secretion in human islets from donors with T2D. We suggest that human islets in T2D display changes reminiscent of dedifferentiation and highlight SOX5 as a regulator of β-cell phenotype and function.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-15, ascites fluid